Literature DB >> 24272838

Computer modeling of the pharmacokinetics of Fluorouracil and thymine and their kinetic interaction in normal dogs.

J M Covey1, J A Straw.   

Abstract

The kinetic behavior of thymine and 5-fluorouracil has been shown to be non-linear and mediated largely by saturable metabolic processes. In vivo estimates of the Michaelis-Menten parameters Vmax and Km were obtained from constant infusion data in normal dogs using a system of balance equations that equate drug input with total output at steady-state. These estimates were then successfully used to simulate both steady-state and post-infusion plasma concentration-time curves for both compounds over a range of saturating and non-saturating conditions. It has been shown previously that estimates of Vmax and Km obtained from dynamic data can be incorrect if an inappropriate compartmental model is used in the analysis. Determining the Michaelis-Menten parameters at steady-state eliminates this difficulty. Moreover, the use of steady-state derived values to simulate post-infusion data confirms the validity of this technique. The kinetic interaction between thymine and 5-fluorouracil was investigated as a case of competitive metabolic inhibition in vivo by calculating Ki values from data obtained during simultaneous constant infusions of the two compounds. These values were then used in conjunction with a series of differential equations incorporating reciprocal metabolic effects to simulate the effect of thymine on FU plasma concentration.

Entities:  

Year:  1985        PMID: 24272838     DOI: 10.1023/A:1016308726772

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  The prevention of methotrexate toxicity by thymidine infusions in humans.

Authors:  W D Ensminger; E Frei
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

2.  Kinetics and mechanisms of drug action of microorganisms XXIII: microbial kinetic assay for fluorouracil in biological fluids and its application to human pharmacokinetics.

Authors:  E R Garrett; G H Hurst; J R Green
Journal:  J Pharm Sci       Date:  1977-10       Impact factor: 3.534

3.  Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas.

Authors:  S F Queener; H P Morris; G Weber
Journal:  Cancer Res       Date:  1971-07       Impact factor: 12.701

Review 4.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

Review 5.  Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences.

Authors:  C Wasternack
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

6.  Thymidine and thymine in biologic fluids during high-dose infusions of thymidine in mice, monkeys, and man.

Authors:  D S Zaharko; B J Bolten; T Kobayashi; R G Blasberg; S S Lee; B C Giovanella; J S Stehlin
Journal:  Cancer Treat Rep       Date:  1979-06

7.  Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.

Authors:  J L Speyer; J M Collins; R L Dedrick; M F Brennan; A R Buckpitt; H Londer; V T DeVita; C E Myers
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

8.  Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs.

Authors:  J M Covey; J A Straw
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

9.  Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.

Authors:  T M Woodcock; D S Martin; L A Damin; N E Kemeny; C W Young
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

10.  Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.

Authors:  J M Collins; R L Dedrick; F G King; J L Speyer; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.